H Oettle

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi [Adjuvant therapy of pancreatic carcinoma]
    H Oettle
    Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin
    Praxis (Bern 1994) 89:2017-25. 2000
  2. ncbi The role of gemcitabine alone and in combination in the treatment of pancreatic cancer
    H Oettle
    Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Anticancer Drugs 11:771-86. 2000
  3. ncbi Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer
    H Oettle
    Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Anticancer Drugs 10:699-704. 1999
  4. ncbi [Adjuvant treatment of pancreatic cancer]
    H Oettle
    Charite Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin, Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie
    Zentralbl Chir 128:411-8. 2003
  5. ncbi A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer
    H Oettle
    Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Ann Oncol 11:1267-72. 2000
  6. ncbi Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer
    Helmut Oettle
    Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Berlin, Germany
    Cancer 95:912-22. 2002
  7. ncbi A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
    H Oettle
    University of Berlin, Berlin, Germany
    Ann Oncol 16:1639-45. 2005
  8. ncbi Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer
    H Oettle
    Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Charite, Campus Virchow Klinikum, Medizinische Facultät der Humboldt Universität zu Berlin, Germany
    Anticancer Drugs 13:833-8. 2002
  9. ncbi Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report
    S Serke
    Department of Haematology Oncology, Charite, Campus Virchow Klinikum, , Berlin, Germany
    Br J Cancer 79:1519-21. 1999
  10. ncbi Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma
    H Oettle
    Charite Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin, Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Berlin, Germany
    Anticancer Drugs 11:635-8. 2000

Detail Information

Publications17

  1. ncbi [Adjuvant therapy of pancreatic carcinoma]
    H Oettle
    Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin
    Praxis (Bern 1994) 89:2017-25. 2000
    ..In a multicenter German trial the benefit of gemcitabene as weekly monotherapy for 6 months is investigated. The treatment starts soon after resection due to low toxicity and good patient compliance...
  2. ncbi The role of gemcitabine alone and in combination in the treatment of pancreatic cancer
    H Oettle
    Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Anticancer Drugs 11:771-86. 2000
    ..The data suggest that gemcitabine in combination with biomodulated 5-FU should be considered the standard palliative treatment to which other new drug combinations or combined modality chemoradiation regimens should be compared...
  3. ncbi Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer
    H Oettle
    Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Anticancer Drugs 10:699-704. 1999
    ..The median time to progressive disease was 31 weeks (range 5-50 weeks). A phase 11 trial is underway to further assess the activity of this combination at the recommended dose of 750 mg/m2 5-FU...
  4. ncbi [Adjuvant treatment of pancreatic cancer]
    H Oettle
    Charite Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin, Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie
    Zentralbl Chir 128:411-8. 2003
    ..These studies have also included arms with gemcitabine, the current standard for palliative treatment of pancreatic cancer, and will hopefully allow firm conclusions as to the role of postoperative chemotherapy...
  5. ncbi A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer
    H Oettle
    Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Ann Oncol 11:1267-72. 2000
    ..The present study was initiated to investigate the efficacy of gemcitabine in combination with 5-FU-FA...
  6. ncbi Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer
    Helmut Oettle
    Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Berlin, Germany
    Cancer 95:912-22. 2002
    ..However, the results of ongoing Phase III studies must be reviewed before a definitive statement can be made regarding the value of this combination in the treatment of pancreatic cancer...
  7. ncbi A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
    H Oettle
    University of Berlin, Berlin, Germany
    Ann Oncol 16:1639-45. 2005
    ..This randomized phase III study compared the overall survival (OS) of pemetrexed plus gemcitabine (PG) versus standard gemcitabine (G) in patients with advanced pancreatic cancer...
  8. ncbi Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer
    H Oettle
    Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Charite, Campus Virchow Klinikum, Medizinische Facultät der Humboldt Universität zu Berlin, Germany
    Anticancer Drugs 13:833-8. 2002
    ....
  9. ncbi Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report
    S Serke
    Department of Haematology Oncology, Charite, Campus Virchow Klinikum, , Berlin, Germany
    Br J Cancer 79:1519-21. 1999
    ..Re-exposure to gemcitabine 6 months after the episode of HUS instituted for progressive carcinoma, thus far has not caused another episode of HUS...
  10. ncbi Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma
    H Oettle
    Charite Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin, Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Berlin, Germany
    Anticancer Drugs 11:635-8. 2000
    ..This opens up an additional therapeutic option for a selected patient group with a poor prognosis so far...
  11. ncbi Presence of human beta- and gamma-herpes virus DNA in Hodgkin's disease
    C A Schmidt
    Abteilung fur Innere Medizin, Hämatologie und Onkologie, Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Leuk Res 24:865-70. 2000
    ..In contrast to EBV, beta-herpes viruses are therefore unlikely to have a role in the aetiology of HD. Rather, the presence of these viruses seems to reflect impaired immunological surveillance...
  12. ncbi Role of F18-FDG PET for monitoring of radiochemotherapy -- estimation of detectable number of tumour cells
    J Ruf
    , Charit, , Campus Virchow-Klinikum, Berlin, Germany
    Onkologie 27:287-90. 2004
    ..CONCLUSION: The number of vital tumour cells within this specimen was estimated to be 10(6)-10(7). The detection threshold for FDG-PET in pancreatic carcinoma appears to be within this range...
  13. ncbi Use of semiflexible applicators for radiofrequency ablation of liver tumors
    G Gaffke
    Klinik für Strahlenheilkunde und Poliklinik, Charite, Universitatsmedizin Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany
    Cardiovasc Intervent Radiol 29:270-5. 2006
    ..To evaluate the feasibility and potential advantages of the radiofrequency ablation of liver tumors using new MRI-compatible semiflexible applicators in a closed-bore high-field MRI scanner...
  14. ncbi Pancreatic cancer: step by step forward
    H Riess
    , Campus Virchow-Klinikum, , Berlin, Germany
    Recent Results Cancer Res 177:1-2. 2008
  15. ncbi Histopathological correlation to MRI findings during and after laser-induced thermotherapy in a pig pancreas model
    C Stroszczynski
    Radiology Charité Campus Buch, Robert Roessle Klinik am Max Delbrueck Center of Molecular Medicine, Berlin, Germany
    Invest Radiol 36:413-21. 2001
    ..To investigate whether percutaneous laser-induced thermotherapy (LITT) with continuous magnetic resonance (MR) monitoring of thermal effects within the pancreas is feasible in a porcine model...
  16. ncbi Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes
    J Däbritz
    Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Augustenburger Platz 1, 13353 Berlin, Germany
    Br J Cancer 92:405-12. 2005
    ..In addition, this method can be adapted for simultanous detection of multiple mutations and quantitation...
  17. ncbi Novel T-cell receptor delta gene rearrangement involving a recombining element located 2.6 kb 3' from the Vdelta2 gene segment
    G K Przybylski
    HU Berlin, UKRV, , Berlin, Germany
    Leuk Res 25:1059-65. 2001
    ..It may potentially lead to deletion of the deltaRec2(Ddelta)Jdelta1 complex and either to direct joining of a Vdelta region to one of the downstream Jdelta regions or to a rearrangement of the TCRalpha gene...